肿瘤治疗电场在脑胶质母细胞瘤治疗中的现状与前景

Current situation and prospect of tumor-treating fields for the treatment of glioblastoma

肿瘤治疗电场是一种新的治疗方法,其通过低强度、中等频率的交变电场干扰肿瘤细胞有丝分裂,从而抑制肿瘤细胞增殖。在治疗复发胶质母细胞瘤患者的临床试验中,肿瘤治疗电场治疗组受试者与经验化疗组受试者相比生存期数据无显著性差异。而在治疗新发胶质母细胞瘤患者的临床试验中,肿瘤治疗电场联合替莫唑胺组受试者与替莫唑胺组受试者相比,生存期显著延长。鉴于肿瘤治疗电场在这两项Ⅲ期临床试验中的优异表现,其被美国国立综合癌症网络(NCCN)指南纳入复发和新发胶质母细胞瘤患者的一线治疗,其产品现已在美国、日本、以色列、中国香港获批准上市。本文对肿瘤治疗电场在脑胶质母细胞瘤治疗中的现状与前景进行综述。

Tumor-treating fields(TTFields)are a new therapeutic method that interferes with the tumor cell mitosis using alternating electric fields with low intensity and medium frequency,thus inhibiting tumor cell proliferation.In a clinical trial involving patients with recurrent glioblastoma,no significant differences were observed in the survival data between the participants who received TTFields therapy and those who received the best available active chemotherapy according to the local physician's choice(HR=0.86,95%CI:0.66-1.12,P=0.27).In clinical trials involving patients newly diagnosed with glioblastoma,those who received TTFields combined with temozolomide therapy had significantly improved progression-free survival(HR=0.63,95%CI:0.52-0.76,P<0.01)and overall survival(HR=0.63,95%CI:0.53-0.76,P<0.01)compared with those who received temozolomide therapy alone.As TTFields were administered in these two stageⅢclinical trials,they have been included in the NCCN guidelines as a first-line treatment for patients with recurrent and new glioblastoma.This therapy is now approved in the United States,Japan,Israel,and Hong Kong,China.This article reviews the current status and prospects of tumor treatment electric fields in the treatment of glioblastoma.